Endologix (ELGX) & The Competition Head-To-Head Survey

Endologix (NASDAQ: ELGX) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Endologix to similar companies based on the strength of its profitability, dividends, risk, earnings, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Endologix and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -41.60% -52.18% -13.70%
Endologix Competitors -100.90% -93.21% -29.92%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Endologix and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 1 7 1 0 2.00
Endologix Competitors 115 734 1032 10 2.50

Endologix presently has a consensus price target of $5.36, suggesting a potential upside of 3.62%. As a group, “Medical Devices & Implants” companies have a potential upside of 40.66%. Given Endologix’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Endologix has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Endologix and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Endologix $192.93 million -$154.67 million -5.56
Endologix Competitors $1.67 billion $207.76 million 58.42

Endologix’s competitors have higher revenue and earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Endologix has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Endologix’s competitors have a beta of 0.30, indicating that their average stock price is 70% less volatile than the S&P 500.

Institutional & Insider Ownership

54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 4.1% of Endologix shares are held by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Endologix competitors beat Endologix on 9 of the 13 factors compared.

About Endologix

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply